Syndax Pharmaceuticals Inc - AUGMENT-101 Data Update And KOL Conference Call Transcript
Good morning, and thank you to everyone for joining us on today's call and webcast to review the exciting interim clinical data from AUGMENT-101, our Phase I/II trial of SNDX-5613 in relapsed and refractory acute leukemia. We especially appreciate our colleagues on the West Coast who may have dialed in at this early hour.
Let me start on Slide 2 with our forward-looking statement. We ask that you please reference our SEC documents to see all the various risk factors that come with investing in Syndax.
Slide 3 is our presenter for today. We are very pleased to Dr. Eytan Stein from the Memorial Sloan Kettering Cancer Center, the principal investigator for the AUGMENT-101 trial, who will present our current Phase I data. I will make a few introductory comments, then Eytan will present the data. I will close with a few comments outlining the next steps for 5613, as well as some commentary on the significant market opportunity for the drug. We should have about 15 to 20 minutes for questions.
Turning to Slide 4.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |